A mom’s $97,000 question: How was her baby’s air-ambulance ride not medically necessary?

Full 1-year results have now been published for the pivotal SELECT-AXIS 2 trial that underpinned the FDA approval of upadacitinib (Rinvoq) for non-radiographic axial spondyloarthritis

The FDA on Thurs­day ap­proved Bris­tol My­ers Squibb’s new schiz­o­phre­nia drug in one of the year’s most an­tic­i­pat­ed reg­u­la­to­ry de­ci­sions. The ap­proval gives Bris­tol My­ers